SCHEDULE 13G/A: Venrock Affiliates Maintain 9.9% Stake in Zura Bio Limited Class A Shares

A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, confirming their collective beneficial ownership of 9.9% of Zura Bio Limited's Class A Ordinary Shares as of March 31, 2025.

Summary

• The filing is an Amendment No. 2 to Schedule 13G for ZURA BIO LIMITED, detailing beneficial ownership.
• The reporting persons constitute a group including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh.
• As of March 31, 2025, the group collectively beneficially owns 7,031,271 Class A Ordinary Shares of Zura Bio Limited.
• This ownership represents 9.9% of the Class A Ordinary Shares outstanding, which was rounded down from 9.99% due to EDGAR filing system limitations.
• The beneficial ownership includes both directly held Class A Ordinary Shares and Pre-Funded Warrants exercisable into Class A Ordinary Shares.
• A 'Beneficial Ownership Blocker' within the Pre-Funded Warrants prevents the group from exercising warrants to the extent that it would result in ownership exceeding 9.99% of the outstanding Class A Ordinary Shares.
• The beneficial ownership percentage is calculated based on 68,374,998 Class A Ordinary Shares outstanding as of March 21, 2025, as reported in Zura Bio's Annual Report on Form 10-K, plus 2,008,105 Class A Ordinary Shares issuable upon the exercise of the Pre-Funded Warrants (within the blocker).

Sentiment

Score: 5

Explanation: Neutral. This is a factual ownership disclosure. It does not convey positive or negative sentiment about the company's performance or prospects, only that a significant investor maintains its stake.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Zura Bio Limited's future performance or strategic outlook. It is solely an ownership disclosure.

Industry Context

This filing is a routine regulatory disclosure of beneficial ownership by a significant institutional investor group. It indicates continued investment interest in Zura Bio Limited by Venrock Healthcare Capital Partners, a firm specializing in healthcare investments. The document does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's continued stake in the company, which can be viewed as a vote of confidence in the long-term prospects of Zura Bio Limited.

Key Dates

Keywords

Zura Bio Limited, SEC Filing, Schedule 13G, Beneficial Ownership, Class A Ordinary Shares, Pre-Funded Warrants, Institutional Investor, Venrock Healthcare Capital Partners, VHCP, Equity Stake